Serrated polyposis syndrome (SPS), also known as hyperplastic polyposis, is a syndrome of unknown genetic basis defined by the occurrence of multiple serrated polyps in the large intestine and associated with an increased risk of colorectal cancer (CRC). There are a variety of SPS presentations, which may encompass a continuum of phenotypes modified by environmental and genetic factors. To explore the phenotype of SPS, we recorded the histologic and molecular characteristics of multiple colorectal polyps in patients with SPS recruited between 2000 and 2010 from genetics clinics in Australia, New Zealand, Canada, and the United States. Three specialist gastrointestinal pathologists reviewed the polyps, which they classified into conventional adenomas or serrated polyps, with various subtypes, according to the current World Health Organization criteria. Mutations in BRAF and KRAS and mismatch repair protein expression were determined in a subset of polyps. A total of 100 patients were selected for the study, of whom 58 were female and 42 were male. The total polyp count per patient ranged from 6 to 150 (median 30). The vast majority of patients (89%) had polyposis affecting the entire large intestine. From this cohort, 406 polyps were reviewed. Most of the polyps (83%) were serrated polyps: microvesicular hyperplastic polyps (HP) (n = 156), goblet cell HP (n = 25), sessile serrated adenoma/polyps (SSA/P) (n = 110), SSA/P with cytologic dysplasia (n = 28), and traditional serrated adenomas (n = 18). A further 69 polyps were conventional adenomas. BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%). Four of 6 SSA/Ps with high-grade dysplasia showed loss of MLH1/ PMS2 expression. CRC was diagnosed in 39 patients who were more often found to have a conventional adenoma compared with patients without CRC (P = 0.003). Patients with SPS referred to genetics clinics had a pancolonic disease with a high polyp burden and a high rate of BRAF mutation. The occurrence of CRC was associated with the presence of conventional adenoma.
S errated polyposis syndrome (SPS), also known as hyperplastic polyposis syndrome, is a colonic polyposis condition predisposing affected individuals to a 25% to 40% risk of developing colorectal cancer (CRC). 3, 5, 6, 17, 24 Although the first few patients with SPS were documented in the 1970s, 8 it has only recently been recognized as a condition with a potential genetic basis, involving serrated polyps as possible precursor lesions to CRC. 15, 16, 21, 29 SPS is reported to occur more commonly in individuals with northern European ancestry and to demonstrate relationships with current smoking, specifically a positive correlation with the number of serrated polyps but a paradoxically negative correlation with the risk of CRC. 5, 6, 33 In addition to multiple serrated polyps, conventional adenomas of the large intestine may be part of the syndrome, as they are identified in up to 85% of SPS patients. 3, 10, 12 Serrated polyps represent a group of benign lesions of the large intestine that have a serrated, saw-toothed appearance and are further classified into 3 categories by the World Health Organization (WHO) Classification of Tumours of the Digestive System 26 : hyperplastic polyp (HP), sessile serrated adenoma/polyp (SSA/P) with or without cytologic dysplasia, and traditional serrated adenoma (TSA). Previously, SPS was called hyperplastic polyposis syndrome when HPs were the only histologically known serrated polyps of the large intestine. Subsequently, studies have described SSA/P as a morphologically distinct and clinically important subset of HP and as a lesion commonly observed in what we now know as SPS. Consequently, the fourth edition of the WHO Classification of Tumours of the Digestive System changed the name of this condition from hyperplastic polyposis to serrated polyposis. 26 The current criteria to define SPS are: (1) at least 5 serrated polyps proximal to the sigmoid colon, with 2 or more of these being >10 mm; or (2) any number of serrated polyps proximal to the sigmoid colon in an individual who has a first-degree relative with serrated polyposis; or (3) >20 serrated polyps of any size but distributed throughout the colon. However, these criteria remain arbitrary, and a meaningful biological classification is more likely to emerge when the genetic basis of the condition is better understood.
There are a variety of presentations in SPS, which may encompass a continuum of phenotypes modified by environmental and genetic factors. It has been suggested that there are 3 phenotypes: large SSA/Ps in the proximal colon with a high risk of CRC; numerous small HPs throughout the colorectum with a lower risk of CRC; and many small left-sided serrated polyps. 13, 17 Moreover, pathways involved in CRC development appear to be heterogenous, not only involving the serrated pathway but also others such as the conventional adenoma pathway. 2 To better understand the phenotype of SPS and its relationship to the occurrence of CRC, we report the histologic and molecular characteristics of colorectal polyps in 100 patients with SPS referred to genetics clinics.
MATERIALS AND METHODS

Patient Selection
Patients were selected from a cohort of individuals with at least 5 serrated polyps in the colon proximal to the recto-sigmoid region recruited between 2000 and 2010 from genetics clinics in Australia, New Zealand, Canada, and the United States. A total of 100 patients for whom definitive serrated polyp counts were available and who fulfilled at least WHO criterion 1 or 3 for SPS 26 were included in this study. None of the patients was selected on the basis of criterion 2 only. Eighty-three patients were referred to genetics clinics for polyposis (with or without a personal or family history of CRC), and 12 were discovered to have polyposis after family screening. Of these 12 patients, 3 met WHO criterion 1, and 9 met criterion 3. No referring details were available for the remaining 5 patients. Thirty-nine patients were from the Australasian Colorectal Cancer Family Registry, and the remaining patients were enrolled in the Genetics of Serrated Neoplasia study (http://www.qimr.edu.au/page/GSN/) to which Ohio State University Medical Center (Columbus, OH), Cancer Care Ontario (Ontario, Canada), the Genetics Clinics of Australia, and the Familial Gastrointestinal Cancer Registry of New Zealand have contributed. 5, 12, 22, 28 Written informed consent was obtained from all patients who took part in the research, and the study was approved by the Human Research Ethics Committee of Queensland Institute of Medical Research under the Genetics of Serrated Neoplasia Project (QIMR HREC P912).
The age at diagnosis was defined by the age at the first observation of polyposis (regardless of the presence or absence of CRC) in the patient. Information on personal characteristics was obtained at the time of recruitment. Reported cancer diagnoses and age at diagnosis were confirmed, where possible, using pathology reports and/or medical records. Standard white light colonoscopy was used in all patients.
Polyp Review
Three specialist gastrointestinal pathologists (J.R.J., N.I.W., and C.R.) reviewed the polyps, which were classified into conventional adenomas or serrated polyps, with its various subtypes, according to the WHO criteria. 26 Information regarding the number, size, distribution, and gross morphology of polyps was derived from the colonoscopy reports. The total numbers for each polyp type were estimated during colonoscopy or from the surgical specimen if a colectomy was performed.
BRAF and KRAS Mutation Analysis
Genomic DNA was extracted from formalin-fixed paraffin-embedded tissue using a QIAamp DNA Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. V600E BRAF mutation analysis was performed by a fluorescent allele-specific polymerase chain reaction (PCR) assay, as previously described. 5 The mutant allele primer generated a PCR product of 97 bp, 3 bp larger than the wild-type PCR product after separation on an ABI 3100 genetic analyzer. GeneMarker (SoftGenetics, State College, PA) software was used to score the alleles on the basis of differing size and fluorophore. KRAS mutation screening was performed using real-time PCR with high-resolution melting analysis, with the primer set AGGCCTGCTGAAAATGACTG (forward primer) and TATCGTCAAGGCACTCTTGC (reverse primer), in the presence of the SYTO9 fluorescent intercalating dye. Direct Sanger sequencing was performed for positive cases.
Mismatch Repair Deficiency Testing
Expression of the MMR proteins MLH1, MSH2, MSH6, and PMS2 was assessed by immunohistochemistry on polyp paraffin sections as described previously. 30 
Statistical Analysis
Statistical analyses were performed with SPSS statistics software version 17.0 (SPSS Inc., Chicago, IL). Comparisons for categorical variables were performed using the Pearson w 2 test or the Fisher exact test when any expected values were <5. The Student t test was used for continuous variables. A 2-tailed P value was used for all analyses, and a P value <0.05 was used to determine statistical significance.
RESULTS
Patient Characteristics
The study comprised 100 patients who fulfilled at least WHO criterion 1 or 3 for SPS (Table 1) . Criterion 1 was met for 12 individuals with polyp counts ranging from 6 to 20 (mean 13.1; median 12). The remaining patients fulfilled criterion 3 with 21 to 150 polyps identified in the large intestine (mean 53.4; median 39). Within criterion 3, a subset of 16 patients also met criterion 1.
There were 58 female and 42 male patients in the study cohort. Age at diagnosis was available for 90 patients and ranged from 17 to 69 years (mean 47.7; SD 14.3). Patients who fulfilled criterion 1 were significantly older than patients who did not (mean age 52.2; SD 14.2 vs. mean age 45.7; SD 14.1; P = 0.049). No significant difference in maximum polyp size or sex was found between these 2 groups.
Polyp Distribution
The total polyp count per patient was estimated to be from 6 to 150 (median 30; mean 45.1; SD 32.6). Ten patients had <20 polyps, and 9 patients had >100 polyps. The maximum recorded size of polyps ranged from 3 to 40 mm (mean 14.9; SD 7.5). Details on the distribution of polyps in the large intestine were obtained for 84 patients. The vast majority of them (89%) had polyposis affecting the entire colon. Proximal colon predominance was described for 6 patients (7%) and distal colorectum predominance for 3 patients (4%) ( Table 1 ).
Histologic Features of Polyps in SPS Patients
Of a total of 4462 polyps identified in the 100 patients, 406 were available for pathologic review, molecular analysis, and immunohistochemistry ( Fig. 1 ). Histologic characteristics of the polyps are summarized in Table 2 . Most of the polyps (83%) were serrated polyps and further subclassified into the following categories: microvesicular HP (n = 156), goblet cell HP (n = 25), SSA/P (n = 110), SSA/P with cytologic dysplasia (n = 28), and TSA (n = 18). In 6 SSA/Ps with cytologic dysplasia, the dysplasia was of a high-grade appearance. SSA/P with or without cytologic dysplasia was more frequently found in the proximal colon compared with microvesicular HPs (63% vs. 36%, P < 0.001). The average reported size of SSA/P was greater than that of all HPs (mean 5.0; SD 2.7 mm vs. mean 3.2; SD 1.8 mm; P < 0.001).
Conventional adenomas represented 17% of all colorectal polyps reviewed in SPS patients, comprising 55 tubular adenomas and 14 tubulovillous adenomas. Tubulovillous adenomas had a significantly larger size compared with tubular adenomas (mean 9.8; SD 5.3 mm vs. mean 3.9; SD 3.4 mm; P < 0.001). High-grade dysplasia was present in a minority of these polyps (6%, 4/69). The majority of conventional adenomas (63%) were located in the proximal colon.
Molecular and Immunohistochemical Findings Associated With Each Polyp Type
Screening for somatic mutation in BRAF was performed for 307 of the 406 polyps (76%) that underwent pathologic review. An informative result was obtained for 270 polyps (88%). Overall, V600E BRAF mutations were detected for 167 polyps in 42 patients. Table 3 shows that the frequency of BRAF mutation, in decreasing order, was 95% in SSA/P with dysplasia, 85% in SSA/P, 76% in microvesicular HP, 54% in TSA, 3% in tubular adenoma, and 0% in tubulovillous adenoma and goblet cell HP. The rate of BRAF mutation was significantly higher in proximally located SSA/Ps compared with distally located SSA/Ps (91% vs. 67%, respectively; P = 0.029). No other difference in BRAF mutation rate was found in other polyp subtypes with regard to their location (Table 3) .
KRAS status was determined for 297 of the 406 polyps with a pathology review, with an informative result in 290 cases (98%). There were KRAS mutations detected for 25 polyps in 16 patients, with the following (Table 4 ). Goblet cell HPs were more likely to harbor KRAS mutation when located in the proximal colon compared with the distal colon (100% vs. 25%; P = 0.009). No other difference in KRAS mutation rate was found in other polyp subtypes with regard to their location. Mismatch repair protein loss of expression was determined in all SSA/Ps with or without dysplasia. Four SSA/Ps showed loss of MLH1/PMS2 expression; all of them were SSA/Ps with high-grade dysplasia.
Association With CRC
In our cohort of 100 SPS patients, information for CRC was available for 93 patients, of whom 39 were diagnosed with CRC (42%), most of them at the time of diagnosis. Table 5 shows that there was no significant difference between patients with and without CRC with regard to sex, age at diagnosis, polyp distribution pattern, and largest polyp size. There was a direct but nonsignificant relationship between polyp count and CRC (P = 0.06). The presence of at least 1 conventional adenoma was associated with the occurrence of CRC (P = 0.003). No significant association was found between a villous component in conventional adenoma and the occurrence of CRC (P = 0.54), or between the presence of SSA/P and CRC (P = 0.23).
DISCUSSION
SPS is a polyposis syndrome of unknown genetic basis defined by the occurrence of multiple serrated polyps in the large bowel and associated with an increased risk for CRC. 3, 5, 6, 24 This study represents one of the largest published cohorts of SPS patients rigorously selected according to the WHO criteria. We characterized the phenotype of these patients with an emphasis on histologic features and molecular alterations of 406 polyps, with a view to identifying features that predict the occurrence of CRC.
Consistent with other previously reported series, 3,17 our results showed that SPS occurs both in male and female patients with age at diagnosis ranging widely from 17 to 69 years (mean 47.7). Interestingly, most patients (89%) presented with a pancolonic distribution of serrated polyps, with a total polyp number ranging from 6 to 150. This is in contrast to previous studies that reported 2 clinical variants 7,13 : type 1 SPS corresponding to criterion 1 of the disease with proximal colonic location of large polyps, BRAF mutation, and high risk of CRC; and type 2 SPS corresponding to criterion 3, with small polyps located throughout the large intestine, KRAS mutation, and lower risk of CRC. In our cohort, 12 patients fulfilled criterion 1 only, whereas the remaining patients fulfilled criterion 3. There was no increased prevalence of CRC in patients with criterion 1 compared with patients with criterion 3. KRAS mutation was a rare event with only 25 instances observed compared with BRAF mutations detected in 167 polyps. Except for goblet cell HP, KRAS mutations were mainly identified in conventional adenomas, which were more commonly located in the proximal colon and associated with higher risk for CRC. Our data indicated that SPS as seen in a tertiary referral setting was mainly a pancolonic disease showing a continuous spectrum of polyp count and location with a median polyp count of 30. Standard white light colonoscopy was used in the majority of patients. The recent introduction of narrow band imaging colonoscopes has shown to improve polyp detection rate, in particular in patients with SPS. 4 It is likely that the median polyp count in our series may actually be >30. Moreover, the recorded size of the polyps was extracted from colonoscopy reports, which may underestimate the true polyp size, especially for sessile polyps. Most large polyps were piecemeal resected, and a histologic size assessment was not possible.
A more recent study has used a nontraditional classification system and suggested that there are 3 SPS phenotypes: proximal, pancolonic, and distal. 17 In that study, patients were derived from clinical databases from a single institution. The age at diagnosis of the patients was considerably greater (mean 62 vs. 47 y), and the serrated polyp burden was considerably less (mean 13 vs. 42) than in our study, which recruited patients from clinical genetics services. Most patients in our study had pancolonic polyposis. As SPS patients seen in genetics services are largely referred for polyp burden, this is not unexpected. The number of criterion 1 cases in our study was, therefore, quite low in comparison, and they had a significantly increased age at onset compared with criterion 3 patients. However, when using either traditional or nontraditional classifications, no relationship was found between criteria and the presence of CRC, which is 1 of 2 significant clinical risks for SPS patients, the other being risk of CRC in first-degree relatives. This finding continues to highlight the need to develop criteria with a biological and clinical basis. Our BRAF and KRAS mutation rates in different polyp subtypes were in agreement with most previously published series. 9, 11, 14, 18, 23, 27, 32 In a recent review reporting collated data gathered from several comparable studies, BRAF mutation frequency was 66.3% in microvesicular HP and 83.9% in SSA/P, compared with 76% and 85% in our study, respectively. 24 We identified 20 SSA/Ps with cytologic dysplasia that showed the highest rate of BRAF mutation (95%). Moreover, loss of MLH1/ PMS2 expression was identified in 67% of SSA/P cases with high-grade dysplasia, whereas this feature was not observed in SSA/P without dysplasia or with low-grade dysplasia. These results are consistent with the hypothesized progression model of serrated neoplasia in which MLH1 methylation is a late event occurring in high-grade lesions with a previously acquired BRAF mutation. 23, 25 With regard to location in the colon, BRAF-mutated SSA/Ps were significantly more common in the proximal colon than in the distal colon. Spring et al 27 previously reported similar findings in a large series of sporadic SSA/ Ps, in which BRAF mutation was found in 85% of proximal SSA/Ps and in 55% of distal SSA/Ps. Interestingly, goblet cell HPs harbored mutation in KRAS more frequently if proximally located compared with when distally located (100% vs. 25%, P = 0.009). Little is known about the significance of goblet HP and their potential for progression to advanced adenoma. In SPS patients, it is possible that proximal goblet cell HPs may represent precursors of more advanced lesions with KRAS mutation, whereas the majority of distal goblet cell HPs may be innocuous lesions with no potential for progression.
TSA was the least common serrated polyp in our series with 18 polyps identified. The prevalence of TSA in polyposis patients and in the general population is not well known. This is likely because of a lack of standardized histologic criteria to diagnose TSA, which can be complicated when conventional dysplasia is superimposed. The rate of mutations in BRAF and KRAS was 54% and 6% in TSA, respectively. Most previous studies reported higher rates of KRAS mutations and lower rates of BRAF mutations in TSA. 19, 20, 23 This discrepancy may be partially due to heterogeneity of the diagnostic criteria. It may also be possible that TSAs arising in SPS patients are different from TSAs arising in the general population. In our series, the majority of TSAs (71%) were located in the proximal colon, whereas it is more commonly found in the distal large bowel sporadically. This difference in location may also account for the higher rate of BRAF mutation in SPS-associated TSA compared with sporadic TSA. It was previously reported that the BRAF mutation occurs at higher frequency in serrated polyps from SPS patients compared with that in the general population. 1, 2, 18 Interestingly, Boparai et al 2 reported a BRAF mutation in all 3 analyzed TSAs from patients with SPS, whereas no KRAS mutation was found in this polyp subtype.
Another important aspect of our study was the presence of at least 1 conventional adenoma in 80% of individuals with SPS, which conferred an increased risk to these patients of being diagnosed with a CRC. Previous studies reported the occurrence of conventional adenoma in 69% to 85% of SPS patients. 3, 10, 12 The increased risk of CRC in these patients, up to 4 times compared with that for SPS patients without conventional adenoma, 5 supports the hypothesis that some CRCs in SPS patients may develop from conventional adenoma through the APC-driven pathway rather than from serrated polyps through the methylation/BRAF-driven pathway. A BRAF mutation has been reported in 33% to 53% of CRCs in SPS patients, 2,31 leaving the balance of CRC developing through a nonserrated pathway and potentially from a conventional adenoma.
The limitations of our study include recruitment of patients from genetics clinics rather than from the general population, with most of them referred for a suspected polyposis condition. This may account for an increased polyp count, a higher proportion of WHO criterion 3 patients, and frequent presentation as a pancolonic disease. It is also possible that a large proportion of asymptomatic SPS patients may carry an average lower count of serrated polyps and may also have a decreased risk of CRC. In summary, we report the phenotype and polyp features in one of the largest published cohorts of SPS patients. Patients with SPS referred to genetics clinics present with a pancolonic polyp distribution, a high polyp burden, and CRC in over 40%. The majority of polyps are of the serrated type with a high frequency of BRAF mutation, including in TSA. The high prevalence of conventional adenoma and the correlation with CRC risk have implications for colonoscopic surveillance and management of patients with SPS, particularly if endoscopic polyp control proves to be difficult.
